Download full-text PDF

Source

Publication Analysis

Top Keywords

augmented gastric
4
gastric inhibitory
4
inhibitory polypeptide
4
polypeptide response
4
response intraduodenal
4
intraduodenal glucose
4
glucose exogenous
4
exogenous gastrin
4
gastrin cholecystokinin
4
augmented
1

Similar Publications

Endoscopic antireflux therapy is widely used in clinical practice. Peroral endoscopic cardial constriction (PECC), antireflux mucosal intervention (ARMI), and radiofrequency ablation (RF) possess analogous antireflux mechanisms. This comprehensive systematic review and meta-analysis aimed to evaluate and compare the safety and effectiveness of antireflux therapy during endoscopic cardia peripheral tissue scar formation (ECSF) procedures.

View Article and Find Full Text PDF

Pyruvate is situated at the intersection of oxidative phosphorylation (OXPHOS) and glycolysis, which are the primary energy-producing pathways in cells. Cancer therapies targeting these pathways have been previously documented, indicating that inhibiting one pathway may lead to functional compensation by the other, resulting in an insufficient antitumor effect. Thus, effective cancer treatment necessitates concurrent and comprehensive suppression of both.

View Article and Find Full Text PDF

Incisional hernias represent a far more common complication after midline incisions than previously estimated. Patients with upper gastrointestinal tract malignancies represent a group of patients at increased risk for incisional hernia formation after undergoing major surgery. Our prospectively designed study included 50 patients who underwent onlay synthetic mesh augmentation of their midline closure along with closure using the small bites technique.

View Article and Find Full Text PDF

Introduction: The first-line standard therapy for advanced HER2-positive gastric cancer is chemotherapy combined with trastuzumab and pembrolizumab, while pembrolizumab alone does not benefit as a monotherapy in patients with mismatch repair proficiency (pMMR). This case explores the therapeutic potential of adding pembrolizumab to patients who were resistant to trastuzumab, focusing on the synergistic effect of an immune checkmate inhibitor, combined with HER2 antibody.

Case Presentation: An 87-year-old metastatic gastric cancer patient, whose medical history was significant for intolerance to chemotherapy and had a poor status of performance.

View Article and Find Full Text PDF
Article Synopsis
  • Immunotherapy shows promise for treating gastric cancer, but resistance to immune checkpoint inhibitors (ICIs) remains a challenge, particularly due to issues with interferon-γ (IFN-γ) signaling.
  • * The study reveals that YTHDF1, an m6A-binding protein, is overexpressed in gastric cancer tissues and negatively impacts IFN-γ responsiveness, correlating with reduced cancer immunity and lower survival rates.
  • * YTHDFs, notably YTHDF1, destabilize IRF1 mRNA, a key player in IFN-γ signaling, indicating their potential as targets for enhancing the effectiveness of cancer immunotherapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!